Updates ON RAS with Daraxonrasib (3/23/26 - 4/13/26)

If you have any questions, please reach out at [email protected] or on Twitter/X @tdonatellov. Thank you for listening!Sources:Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic CancerIDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal MelanomaAllogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCLGSK presents positive data for B7-H4-targeted ADC in gynecological cancersCorrections:Stated that there are >300 primary uveal melanona cases annually in the U.S., this figure is actually >3000 cases. Did not mention that the OptimUM-02 trial of darovasertib + crizotinib included 437 patients randomized 2:1 to darovasertib + crizotinib or investigator's choice